Clinical Application of High-Dose, Image-Guided Intensity-Modulated Radiotherapy in High-Risk Prostate Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 77, Issue 2, 2010, Pages 477-483

  Bayley, Andrew ^a   Rosewall, Tara ^a   Craig, Tim ^a   Bristow, Rob ^a   Chung, Peter ^a   Gospodarowicz, Mary ^a   Ménard, Cynthia ^a   Milosevic, Michael ^a   Warde, Padraig ^a   Catton, Charles ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Dose escalation; Intensity modulated radiation therapy; Pelvic radiotherapy; Prostate cancer; Toxicity

Indexed keywords

DOSE ESCALATION; INTENSITY MODULATED RADIATION THERAPY; PELVIC RADIOTHERAPY; PROSTATE CANCER; PROSTATE CANCERS;

PHYSICAL THERAPY; TOXICITY;

RADIOTHERAPY;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; FECES INCONTINENCE; FOLLOW UP; HEMATURIA; HIGH RISK PATIENT; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTESTINE WALL; MAJOR CLINICAL STUDY; MALE; NOCTURIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROSTATE CANCER; RECTUM HEMORRHAGE; SEMINAL VESICLE; URINARY FREQUENCY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; FEASIBILITY STUDIES; HUMANS; LYMPHATIC IRRADIATION; MALE; MIDDLE AGED; PELVIS; PROSPECTIVE STUDIES; PROSTATE; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; SEMINAL VESICLES; URINATION DISORDERS;

EID: 77951949957     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.05.006     Document Type: Article

References (30)

1. Lawton C.A., Winter K., Murray K., et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 49 (2001) 937-946
2. Pilepich M.V., Winter K., John M.J., et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50 (2001) 1243-1252
3. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 360 (2002) 103-106
4. Roach III M., DeSilvio M., Lawton C., et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21 (2003) 1904-1911
5. Zelefsky M.J., Yamada Y., Fuks Z., et al. Long-term results of conformal radiotherapy for prostate cancer: Impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 71 (2008) 1028-1033
6. Zelefsky M.J., Fuks Z., Wolfe T., et al. Locally advanced prostatic cancer: Long-term toxicity outcome after three-dimensional conformal radiation therapy-a dose-escalation study. Radiology 209 (1998) 169-174
7. Zapatero A., Rios P., Marin A., et al. Dose escalation with three-dimensional conformal radiotherapy for prostate cancer. Is more dose really better in high-risk patients treated with androgen deprivation?. Clin Oncol (R Coll Radiol) 18 (2006) 600-607
8. Jacob R., Hanlon A.L., Horwitz E.M., et al. Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement. Int J Radiat Oncol Biol Phys 61 (2005) 695-701
9. Pommier P., Chabaud S., Lagrange J.L., et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 25 (2007) 5366-5373
10. Lawton C.A., DeSilvio M., Roach III M., et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: Updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 69 (2007) 646-655
11. Forman J.D., Lee Y., Roberson P., et al. Advantages of CT and beam's eye view display to confirm the accuracy of pelvic lymph node irradiation in carcinoma of the prostate. Radiology 186 (1993) 889-892
12. Bonin S.R., Lanciano R.M., Corn B.W., et al. Bony landmarks are not an adequate substitute for lymphangiography in defining pelvic lymph node location for the treatment of cervical cancer with radiotherapy. Int J Radiat Oncol Biol Phys 34 (1996) 167-172
13. Dirix P., Haustermans K., Junius S., et al. The role of whole pelvic radiotherapy in locally advanced prostate cancer. Radiother Oncol 79 (2006) 1-14
14. Roach M., Marquez C., Yuo H.S., et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 28 (1994) 33-37
15. Parker C.C., Damyanovich A., Haycocks T., et al. Magnetic resonance imaging in the radiation treatment planning of localized prostate cancer using intra-prostatic fiducial markers for computed tomography co-registration. Radiother Oncol 66 (2003) 217-224
16. Moseley D., White E., Wiltshire K., et al. Comparison of localization performance with implanted fiducial marker and cone-beam computed tomography for on-line image guided radiotherapy of the prostate. Int J Radiat Oncol Biol Phys 67 (2007) 942-953
17. Chung P.W., Haycocks T., Brown T., et al. On-line aSi portal imaging of implanted fiducial markers for the reduction of interfraction error during conformal radiotherapy of prostate carcinoma. Radiother Oncol 60 (2004) 942-953
18. Wu J., Haycocks T., Alasti H., et al. Positioning errors and prostate motion during conformal prostate radiotherapy using on-line isocentre setup verification and implanted prostate markers. Radiother Oncol 61 (2001) 1271-1233
19. Dinniwell R., Chan P., Haider M., et al. Development of a three-dimensional anisotropic pelvic lymph node clinical target volume using magnetic resonance lymphography with ferumoxtran-10. Int J Radiat Oncol Biol Phys 74 (2009) 844-851
20. Yan J., Bayley A., Rosewall T., et al. A strategy for image guidance during loco-regional IMRT to prostate, seminal vesicles, and pelvic lymph nodes. Int J Radiat Oncol Biol Phys 69 (2007) S345-S346
21. Skala M., Rosewall T., Dawson L., et al. Patient-assessed late toxicity rates and principal component analysis after image-guided radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 68 (2007) 690-698
22. Zurlo A., Collette L., van Tienhoven G., et al. Acute toxicity of conventional radiation therapy for high-risk prostate cancer in EORTC trial 22863. Eur Urol 42 (2002) 125-132
23. Roach III M., DeSilvio M., Valicenti R., et al. Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys 66 (2006) 647-653
24. Sanguineti G., Endres E.J., Parker B.C., et al. Acute toxicity of whole-pelvis IMRT in 87 patients with localized prostate cancer. Acta Oncol 47 (2008) 301-310
25. Dearnaley D. Phase 1 study of dose escalated intensity modulated radiation therapy (IMRT) to the prostate and pelvis in men with high risk localized disease treated with adjuvant androgen suppression. In: Oncology ASCO. ASCO Prostate Cancer Symposium 2007. www.asco.org San Francisco: American Society of Clinical Oncology; 2007 (abstract no. 165).
26. Arcangeli S., Saracino B., Petrongari M.G., et al. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area. Radiother Oncol 84 (2007) 148-155
27. Muren L.P., Wasbo E., Helle S.I., et al. Intensity-modulated radiotherapy of pelvic lymph nodes in locally advanced prostate cancer: Planning procedures and early experiences. Int J Radiat Oncol Biol Phys 71 (2008) 1034-1041
28. Michalski J.M., Lawton C., El-Naqa I., et al. Variation in the definition of clinical target volumes for postoperative conformal radiation therapy of prostate cancer. Int J Radiat Oncol Biol Phys 69 (2007) S326
29. Harisinghani M.G., Barentsz J., Hahn P.F., et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348 (2003) 2491-2499
30. Fowler J.F., Chappell R.J., and Ritter M.A. The prospects for new treatments for prostate cancer. Int J Radiat Oncol Biol Phys 52 (2002) 3-5